Amal Abdul-Hafez

Dr. Amal Abdul-Hafez

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2008 in American Journal of Physiology-Lung Cellular and Molecular Physiology
Verified
Journal Article
Closed access
PDF file
XLXiaopeng Li
Xiaopeng Li
MMMaria Molina-Molina
Maria Molina-Molina
AAAmal Abdul-Hafez
Amal Abdul-Hafez
VUVictor Uhal
Victor Uhal
AXAntonio Xaubet
Antonio Xaubet
BUBruce Uhal
Bruce Uhal
Earlier work from this laboratory showed that local generation of angiotensin (ANG) II is required for the pathogenesis of experimental pulmonary fibrosis and that ANG peptides are expressed robustly in the lungs of patients with idiopathic pulmonary fibrosis (IPF). Angiotensin converting enzyme-2 (ACE-2) degrades the octapeptide ANG II to form the heptapeptide ANG1-7 and thereby limits ANG II accumulation. On this basis, we hypothesized that ACE-2 would be protective against experimental lung fibrogenesis and might be downregulated in human and experimental lung fibrosis. In lung biopsy specimens from patients with IPF, ACE-2 mRNA and enzyme activity were decreased by 92% ( P < 0.01) and 74% ( P < 0.05), respectively. ACE-2 mRNA and activity were also decreased similarly in the lungs of bleomycin-treated rats and C57-BL6 mice. In mice exposed to low doses of bleomycin, lung collagen accumulation was enhanced by intratracheal administration of either ACE-2-specific small interfering RNAs (siRNAs) or the peptide DX600, a competitive inhibitor of ACE-2 ( P < 0.05). Administration of either ACE-2 siRNA or DX600 significantly increased the ANG II content of mouse lung tissue above the level induced by bleomycin alone. Coadministration of the ANG II receptor antagonist saralasin blocked the DX600-induced increase in lung collagen. Moreover, purified recombinant human ACE-2, delivered to mice systemically by osmotic minipump, attenuated bleomycin-induced lung collagen accumulation. Together, these data show that ACE-2 mRNA and activity are severely downregulated in both human and experimental lung fibrosis and suggest that ACE-2 protects against lung fibrogenesis by limiting the local accumulation of the profibrotic peptide ANG II.

1 September 2011 in American Journal of Physiology-Lung Cellular and Molecular Physiology
Verified
Journal Article
Closed access
PDF file
BUBruce Uhal
Bruce Uhal
XLXiaopeng Li
Xiaopeng Li
AXAnita Xue
Anita Xue
XGXu Gao
Xu Gao
AAAmal Abdul-Hafez
Amal Abdul-Hafez
Earlier work from this laboratory demonstrated that apoptosis of alveolar epithelial cells (AECs) requires autocrine generation of angiotensin (ANG) II. More recent studies showed that angiotensin converting enzyme-2 (ACE-2), which degrades ANGII to form ANG1–7, is protective but severely downregulated in human and experimental lung fibrosis. Here it was theorized that ACE-2 and its product ANG1–7 might therefore regulate AEC apoptosis. To evaluate this hypothesis, the AEC cell line MLE-12 and primary cultures of rat AECs were exposed to the profibrotic apoptosis inducers ANGII or bleomycin (Bleo). Markers of apoptosis (caspase-9 or -3 activation and nuclear fragmentation), steady-state ANGII and ANG1–7, and JNK phosphorylation were measured thereafter. In the absence of Bleo, inhibition of ACE-2 by small interfering RNA or by a competitive inhibitor (DX600 peptide) caused a reciprocal increase in autocrine ANGII and corresponding decrease in ANG1–7 in cell culture media (both P < 0.05) and, moreover, induced AEC apoptosis. At baseline (without inhibitor), ANG1–7 in culture media was 10-fold higher than ANGII (P < 0.01). Addition of purified ANGII or bleomycin-induced caspase activation, nuclear fragmentation, and JNK phosphorylation in cultured AECs. However, preincubation with ANG1–7 (0.1 μM) prevented JNK phosphorylation and apoptosis. Moreover, pretreatment with A779, a specific blocker of the ANG1–7 receptor mas, prevented ANG1–7 blockade of JNK phosphorylation, caspase activation, and nuclear fragmentation. These data demonstrate that ACE-2 regulates AEC survival by balancing the proapoptotic ANGII and its antiapoptotic degradation product ANG1–7. They also suggest that ANG1–7 inhibits AEC apoptosis through the ANG1–7 receptor mas.

1 November 2006 in American Journal of Physiology-Lung Cellular and Molecular Physiology
Verified
Journal Article
Closed access
PDF file
XLXiaopeng Li
Xiaopeng Li
MMMaria Molina-Molina
Maria Molina-Molina
AAAmal Abdul-Hafez
Amal Abdul-Hafez
JRJose Ramirez
Jose Ramirez
ASAnna Serrano-Mollar
Anna Serrano-Mollar
BUBruce D. Uhal
Bruce D. Uhal
Previous work from this laboratory demonstrated de novo synthesis of angiotensin (ANG) peptides by apoptotic pulmonary alveolar epithelial cells (AEC) and by lung myofibroblasts in vitro and in bleomycin-treated rats. To determine whether these same cell types also synthesize ANG peptides de novo within the fibrotic human lung in situ, we subjected paraffin sections of normal and fibrotic (idiopathic pulmonary fibrosis, IPF) human lung to immunohistochemistry (IHC) and in situ hybridization to detect ANG peptides and angiotensinogen (AGT) mRNA. These were analyzed both alone and in combination with cell-specific markers of AEC [monoclonal antibody (MAb) MNF-116] and myofibroblasts [α-smooth muscle actin (α-SMA) MAb] and an in situ DNA end labeling (ISEL) method to detect apoptosis. In normal human lung, IHC detected AGT protein in smooth muscle underlying normal bronchi and vessels, but not elsewhere. Real-time RT-PCR and Western blotting revealed that AGT mRNA and protein were 21-fold and 3.6-fold more abundant, respectively, in IPF lung biopsies relative to biopsies of normal human lung (both P < 0.05). In IPF lung, both AGT protein and mRNA were detected in AEC that double-labeled with MAb MNF-116 and with ISEL, suggesting AGT expression by apoptotic epithelia in situ. AGT protein and mRNA also colocalized to myofibroblast foci detected by α-SMA MAb, but AGT mRNA was not detected in smooth muscle. These data are consistent with earlier data from isolated human lung cells in vitro and bleomycin-induced rat lung fibrosis models, and they suggest that apoptotic AEC and myofibroblasts constitute key sources of locally derived ANG peptides in the IPF lung.

9 April 2022 in Cells
Verified
Journal Article
Open access
PDF file
SOSaid Omar
Said Omar
AAAmal Abdul-Hafez
Amal Abdul-Hafez
Sherif IbrahimSherif Ibrahim
Sherif Ibrahim
NPNatasha Pillai
Natasha Pillai
MAMohammed Abdulmageed
Mohammed Abdulmageed
BUBruce Uhal
Bruce Uhal
Premature newborns are at a higher risk for the development of respiratory distress syndrome (RDS), acute lung injury (ALI) associated with lung inflammation, disruption of alveolar structure, impaired alveolar growth, lung fibrosis, impaired lung angiogenesis, and development of bronchopulmonary dysplasia (BPD) with severe long-term developmental adverse effects. The current therapy for BPD is limited to supportive care including high-oxygen therapy and pharmacotherapy. Recognizing more feasible treatment options to improve lung health and reduce complications associated with BPD is essential for improving the overall quality of life of premature infants. There is a reduction in the resident stem cells in lungs of premature infants with BPD, which strongly suggests a critical role of stem cells in BPD pathogenesis; this warrants the exploration of the potential therapeutic use of stem-cell therapy. Stem-cell-based therapies have shown promise for the treatment of many pathological conditions including acute lung injury and BPD. Mesenchymal stem cells (MSCs) and MSC-derived extracellular vesicles (EVs) including exosomes are promising and effective therapeutic modalities for the treatment of BPD. Treatment with MSCs and EVs may help to reduce lung inflammation, improve pulmonary architecture, attenuate pulmonary fibrosis, and increase the survival rate.
1

25 October 2012 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
BUBruce Uhal
Bruce Uhal
MDMyTrang Dang
MyTrang Dang
VDVinh Dang
Vinh Dang
RLRoger Llatos
Roger Llatos
ECEsteban Cano
Esteban Cano
MMMaria Molina-Molina
Maria Molina-Molina
Alveolar epithelial type II cells, a major source of angiotensin-converting enzyme (ACE)-2 in the adult lung, are normally quiescent but actively proliferate in lung fibrosis and downregulate this protective enzyme. It was, therefore, hypothesised that ACE-2 expression might be related to cell cycle progression.To test this hypothesis, ACE-2 mRNA levels, protein levels and enzymatic activity were examined in fibrotic human lungs and in the alveolar epithelial cell lines A549 and MLE-12 studied at postconfluent (quiescent)versussubconfluent (proliferating) densities.ACE-2 mRNA, immunoreactive protein and enzymatic activity were all high in quiescent cells, but were severely downregulated or absent in actively proliferating cells. Upregulation of the enzyme in cells that were progressing to quiescence was completely inhibited by the transcription blocker actinomycin D or by SP600125, an inhibitor of c-Jun N-terminal kinase (JNK). In lung biopsy specimens obtained from patients with idiopathic pulmonary fibrosis, immunoreactive enzyme was absent in alveolar epithelia that were positive for proliferation markers, but was robustly expressed in alveolar epithelia devoid of proliferation markers.These data explain the loss of ACE-2 in lung fibrosis and demonstrate cell cycle-dependent regulation of this protective enzyme by a JNK-mediated transcriptional mechanism.

11 February 2009 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
AAAmal Abdul-Hafez
Amal Abdul-Hafez
RSRuijie Shu
Ruijie Shu
BUBruce Uhal
Bruce Uhal
Earlier work showed that TGF‐β 1 potently increases angiotensinogen (AGT) gene mRNA in primary human lung fibroblasts. Here the mechanism of TGF‐β 1‐induced AGT expression was studied in the IMR90 human lung fibroblast cell line. The increase in AGT mRNA induced by TGF‐β 1 was completely blocked by actinomycin‐D. TGF‐β 1 increased the activity of a full‐length human AGT promoter‐luciferase reporter (AGT‐LUC) but did not alter AGT mRNA half‐life. Serial deletion analyses revealed that 67% of TGF‐β‐inducible AGT‐LUC activity resides in a small domain of the AGT core promoter;this domain contains binding sites for hypoxia‐inducible factor (HIF)‐1 and activationprotein‐1 (AP‐1) transcription factors. TGF‐β1 increasedHIF‐1α protein abundance and the activity of a hypoxia‐responsive element reporter;overexpression ofHIF‐1 increased basal AGT‐LUC activity. Both oligonucleotide pulldown and chromatin immunoprecipita‐tion assays revealed increased binding of JunD andHIF‐1 α to the AGT core promoter in response to TGF‐β1. TGF‐β1‐inducible AGT‐LUC was reduced by anAP‐1 dominant negative or by mutation of theAP‐1 site. Knockdown of either JunD orHIF‐1α individually by siRNA partially reduced AGT‐LUC. In contrast, simultaneous knockdown of both JunD andHIF‐1α completely eliminated TGF‐β 1‐inducible AGT‐LUC activity. These data suggest that TGF‐β 1 up‐regulates AGT transcription in human lung fibroblasts through a mechanism that requires both JunD andHIF‐1α binding to the AGT core promoter. They also suggest a molecular mechanism linking hypoxia signaling and fibrogenic stimuli in the lungs.—Abdul‐Hafez, A.,Shu, R., Uhal, B.D. JunD andHIF‐1a mediate transcriptional activation of angiotensinogen by TGF‐P 1 in human lung fibroblasts. FASEB J. 23, 1655–1662 (2009)